Insulet Corporation (PODD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
39.53-3.29 (-7.68%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close42.82
Bid38.15 x 100
Ask0.00 x
Day's Range39.32 - 42.65
52wk Range23.94 - 45.60
1y Target EstN/A
Market Cap2.26B
P/E Ratio (ttm)-35.81
Avg Vol (3m)563,865
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Reutersyesterday

    U.S. FDA approves Medtronic's 'artificial pancreas' for diabetes

    Medtronic Plc won U.S. approval on Wednesday for an "artificial pancreas" that is the first device to automatically deliver the right dose of insulin to patients with type 1 diabetes, freeing them from continually monitoring insulin levels throughout each day. The U.S. Food and Drug Administration, in its approval of the device, the MiniMed 670G, hailed it as a breakthrough. The device offers type 1 diabetics "greater freedom to live their lives without having to consistently and manually monitor baseline glucose levels and administer insulin," Dr. Jeffrey Shuren, director of the FDA's medical device division, said in a statement.

  • Business Wire3 days ago

    Insulet Corporation to Announce Third Quarter 2016 Financial Results on November 3, 2016

    Insulet Corporation , the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the third quarter of 2016 on November 3, 2016 after the close of the financial markets.

  • Business Wire17 days ago

    Insulet Enrolls First Patients in Clinical Trial for its Omnipod® Artificial Pancreas System

    Insulet Corporation  , the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System , today announced the first patient has completed the feasibility study of the Omnipod Horizon™ Automated Glucose Control System .